MEDIF - This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023 Trims Losses | Benzinga
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results on Wednesday for the full year and three months ended Dec. 31, 2023.
Net revenue grew to CA$33 million ($24.3 million) in 2023, from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase, the company said in a press release.
"Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," CEO David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs.”
Top executives leading some of the largest cannabis operators are slated to share revenue growth tips and other valuable business insights at the upcoming Benzinga Cannabis Capital Conference in Florida on April 16-17.
The two-day event that returns to The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow.